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Summary
Background: Cervical cancer remains an important health problem even in countries with effec-
tive cervical screening programs. HPV vaccines offer great potential for primary prevention of
cervical cancer and other HPV-related diseases.
Perspectives: Eventual implementation of an HPV vaccination program raises several key issues,
including universal vs. targeted vaccinations, the age and gender of vaccine recipients, the
acceptability of this vaccine to health care providers, adolescents, and parents, and the effect
of this vaccine on cervical cancer screening. These issues were explored among symposium
attendees during an interactive question-and-answer session using computerized voting pads.
Conclusions: Preventative HPV vaccination programs should ideally be executed universally in
both women and men with an emphasis on children and adolescents prior to their first sexual
experience. Parent education on HPV disease and vaccine efficacy and safety will be critical to
the acceptability of HPV vaccination for their children. HPV vaccination will not eliminate the
need for Pap screening. Further research will be needed to develop rational and cost-effective
cervical surveillance programs for women protected by HPV vaccines.
© 2007 International Society for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.
Introduction
Late-phase clinical trials have generated a plethora of
promising clinical data relating to the efficacy of human
papillomavirus (HPV) vaccines to prevent cervical dysplasia
and other HPV-related diseases (reviewed by Professors
Frazer and Villa in this supplement). However, several
key issues remain concerning the eventual implementa-
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tion of an HPV vaccination program, including universal
vs. targeted vaccinations, the age and gender of vaccine
recipients, the acceptability of this vaccine to health care
providers, adolescents, and parents, and the effect of this
vaccine on cervical cancer screening. The purpose of this
article is to explore these topics and briefly summarize
feedback obtained from symposium attendees during an in-
teractive question-and-answer session using computerized
voting pads.
Universal vs. targeted vaccination
HPV infection is widespread with a lifetime risk of HPV
infection for sexually active men and women estimated to
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be more than 50%.1 As a result, it is impossible to identify
an at-risk group to target for vaccination. Routine universal
vaccination aims at reaching most potential carriers of
any virus and, thus, is more likely to produce substantial
reductions in HPV disease burden over the long term.
The hepatitis B immunization experience provides an
interesting example of the benefit of universal vs. targeted
vaccination (Figure 1). The Centers for Disease Control
in the USA found that universal immunization of infants
combined with “catch-up” immunization of adolescents for
a limited number of years achieve the most rapid reduction
of hepatitis B incidence.2,3
Polling of the audience attending this symposium in-
dicated that most (78.5%) agreed that preventive HPV
vaccination should be performed on a broad age-range
cohort , including all 9---10 year olds and 11---26 year olds as
well as older individuals who could still benefit from vacci-
nation. This view is consistent with the highest risk of HPV
infection occurring in adolescents 15---19 years of age and
the risk of HPV infection acquisition continuing throughout
life.4 In a cohort of HPV-negative Colombian women 15---85
years of age, the highest five-year cumulative risk (42.5%)
occurred among women 15---19 years of age, but risk in
women 45 years of age and older was still high (12.4%).4
Vaccinating both genders vs. females only
The greatest pathologic burden of HPV infection unques-
tionably occurs in women, but men serve as vectors for
HPV transmission to women and develop a variety of HPV-
related diseases such as genital warts and anal cancer.5,6
Since gender-specific vaccination programs, such as the
rubella vaccination program that focused on vaccinating
girls only were not effective, the clinical development
program for the quadrivalent HPV vaccine also includes
studies on the immunogenicity, efficacy, and tolerability in
males. The audience overwhelming supported (78.9%) the
contention that HPV vaccination should be administered
routinely to both females and males.
Ideal age for vaccination
The choice of ideal age to vaccinate against HPV is in-
fluenced by the impact of age on the magnitude of the
immune response to HPV vaccination and by the age of sex-
ual debut of adolescents. As reviewed by Professor Frazer
Figure 1 Modeled reduction in hepatitis B cases based on various immunization strategies. Reproduced from Margolis H, Alter M, Krugman
S. In: Hollinger BF, Lemon SM, Margolis H, eds. Baltimore, Md: Williams & Wilkins; 1991:720---7222.3
(this supplement), a robust immune response to a quadri-
valent HPV vaccine occurs in children aged 9 through young
adults aged 26. Immunogenicity bridging studies indicate
that the greatest anti-HPV levels occur in prepubertal
children (9 to 12 years). Since HPV infection often occurs
within months after sexual debut, which can be less than
13 years of age for many adolescents throughout the world,
it follows that maximum protection from an HPV vaccine
would be expected to occur when children and adoles-
cents are vaccinated prior to their first sexual experience.
Vaccinating against HPV at this age would be compatible
with the current adolescent immunization schedules for
tetanus, diphtheria, polio, measles, mumps, and rubella in
some countries, including the USA, UK, Germany, Spain,
and France; however, variations from country to country do
exist.
Approximately one third (32%) of symposium partici-
pants believed that the ideal age of the primary cohort for
routine vaccination against HPV should be 9 to 10 years
old. An additional third (32%) thought that the ideal age for
vaccination should be 9 to 13 years old and a further 20%
indicated that vaccination should take place across young
people of all ages (9 to 26 years).
Importance of parent education on
acceptability of HPV vaccination in young
adolescents
While many consumers are not familiar with HPV and
often confuse it with human immunodeficiency virus, par-
ents nevertheless have high levels of interest in an HPV
vaccine for their children. Understanding the key issues
in parental acceptance of HPV vaccination of adolescents
will be critical to the development and implementation of
effective HPV immunization programs. According to studies
conducted in the US, UK, and Mexico, parents are willing to
vaccinate their children once they are properly informed
about HPV; if they believe their children will likely be
exposed to HPV; and if the benefits outweigh risks.8- 12
Several factors are important for parental acceptability
of an HPV vaccine,9,12,13 including disease severity, vac-
cine efficacy, physician recommendation, and the parents'
personal history of the disease. Not surprisingly, physi-
cians' acceptance and communication about the vaccine
appear to have the greatest influence in motivating par-
ents to have their children vaccinated. Audience polling
indicated that approximately 84% of attendees consid-
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ered parent education to be influential or very influential
for parents' acceptability of HPV vaccination of young
adolescents.
HPV vaccination complementary to a cervical
screening program
Detection of early cervical cytological abnormalities using
the subjective Papanicolaou (Pap) test is an effective tool
in reducing (but not eliminating) the burden of cervical
cancer. However, the Pap test has a number of technical
limitations, including high false positive and false nega-
tive rates due to errors in interpretation, poor sample
collection and poor slide preparation.14 In addition, even
in countries with well organized Pap cytological screening
programs, cervical cancer is still unacceptably high.
The development of HPV vaccines promises effective
primary prevention of cervical cancer and has created a
dilemma for healthcare policy makers about the future
scope of cervical cancer screening. Two factors are rele-
vant to screening programs. The first is that current HPV
vaccines do not cover all the HPV types capable of causing
cervical cancer. The second is that only vaccinees will
be protected; thus, the full impact of HPV vaccination
on cervical cancer will take many decades to evolve.
While HPV vaccination may result in less referrals, less
frequent re-screenings, and less procedures in the not-too-
distant future, it would be premature at this juncture to
lessen our vigilance in screening for cervical cancer. In
other words, vaccination will not eliminate the need for
screening. However, when used in concert, screening and
vaccination may help prevent more cervical cancers than
either would alone and would result in fewer Pap smears,
fewer colposcopy procedures, and fewer clinic visits by
preventing the low-level cervical dysplasia that would have
been caused by the HPV strains in the vaccine. A majority
of the audience concurred with this assertion, with 48% of
attendees believing that cervical cancer screening will not
change as a result of HPV vaccination.
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